StockNews.AI
NPCE
StockNews.AI
197 days

NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th

1. NeuroPace presents RNS System study at AAN 2025 Annual Meeting. 2. Research focuses on outcomes for focal epilepsy patients. 3. Presentation may increase visibility and credibility for NeuroPace. 4. The RNS System is the first brain-responsive epilepsy treatment. 5. Potential to improve care for drug-resistant epilepsy patients.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive presentation at AAN can enhance investor confidence, similar to past medical conferences boosting stocks.

How important is it?

The abstract's selection signals potential advancements in epilepsy treatment, likely impacting investors' perception.

Why Short Term?

Immediate interest from presentation can drive short-term price momentum, as seen with other medical announcements.

Related Companies

RNSNEUROAAN
February 03, 2025 16:05 ET  | Source: NeuroPace, Inc. MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego. Presentation Details:Title:Multicenter Post-approval Study of the RNS System in Focal EpilepsyPresenter:Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of the UCLA Seizure Disorders CenterSession:S20: Epilepsy Clinical Outcomes and PrognosticationPresentation number:009Date and Time:Monday, April 7th, at 5:06 PM PT   About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Investor Contact:Jeremy Feffer Managing Director LifeSci Advisorsjfeffer@lifesciadvisors.com

Related News